Updated: Stealth biotech Perceive raises $78M from J&J and Deerfield, says little about eye disease programs

Lei Lei Wu

News Reporter

Eye disease biotech Perceive Biotherapeutics announced Thursday that it has raised $78 million in a Series B, though it says it is remaining in stealth …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Stealth biotech Perceive raises $78M from J&J and Deerfield, says little about eye disease programs

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: CRISPR delivery startup, based on UC Berkeley and UCSF science, shuts down

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Startup that mines ‘junk DNA’ secures R&D deal with Merck

Will CRISPR matter?

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­dat­ed: Stealth biotech Per­ceive rais­es $78M from J&J and Deer­field, says lit­tle about eye dis­ease pro­grams

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Updated: Stealth biotech Perceive raises $78M from J&J and Deerfield, says little about eye disease programs